SynthesisDiabetes, obesity & metabolism2016

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.

A Salsali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.